ONCAlert | 2018 ASCO Annual Meeting

A Phase Ib Study of Pembrolizumab in Bladder Cancer

Elizabeth Plimack, MD, MS
Published Online: 6:59 PM, Wed October 1, 2014
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

Clinical Pearls

  • 33 patients with urothelial tract cancer were enrolled on this trial.
  • A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
  • Overall survival data seen in this study were at the top bound of historical data.

<<< View more from the 2014 ESMO Congress

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.